(AFX UK Focus) 2009-06-25 07:22 UPDATE 1-Japan approves Novartis' generic biotech drug (Interactive Investor) Print

ZURICH, June 25 (Reuters) - Japanese regulators have approved a human growth hormone from Novartis AG, the first green light in Japan for a biosimilar or generic version of a biotech drug, the Swiss drugmaker said on Thursday. Somatropin, made by Novartis' generics unit Sandoz, is for treatment of growth hormone deficiency in children and growth disturbance associated with Turner's syndrome or ...

read more